HomeCompareBPTS vs GBDC

BPTS vs GBDC: Dividend Comparison 2026

BPTS yields 24.33% · GBDC yields 11.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBDC wins by $20.68M in total portfolio value· pulled ahead in Year 3
10 years
BPTS
BPTS
● Live price
24.33%
Share price
$8.22
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$94.9K
Annual income
$10,445.94
Full BPTS calculator →
GBDC
GBDC
● Live price
11.85%
Share price
$12.66
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.78M
Annual income
$16,389,263.41
Full GBDC calculator →

Portfolio growth — BPTS vs GBDC

📍 GBDC pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBPTSGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BPTS + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BPTS pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BPTS
Annual income on $10K today (after 15% tax)
$2,068.13/yr
After 10yr DRIP, annual income (after tax)
$8,879.05/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.11/yr
After 10yr DRIP, annual income (after tax)
$13,930,873.90/yr
At 15% tax rate, GBDC beats the other by $13,921,994.85/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BPTS + GBDC for your $10,000?

BPTS: 50%GBDC: 50%
100% GBDC50/50100% BPTS
Portfolio after 10yr
$10.44M
Annual income
$8,199,854.67/yr
Blended yield
78.58%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

BPTS
Analyst Ratings
1
Buy
Consensus: Buy
Price Target
$15.00
+82.5% upside vs current
Range: $15.00 — $15.00
Altman Z
-13.4
Piotroski
2/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.6% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BPTS buys
0
GBDC buys
0
No recent congressional trades found for BPTS or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBPTSGBDC
Forward yield24.33%11.85%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$94.9K$20.78M
Annual income after 10y$10,445.94$16,389,263.41
Total dividends collected$59.3K$20.36M
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy
Analyst price target$15.00$14.00

Year-by-year: BPTS vs GBDC ($10,000, DRIP)

YearBPTS PortfolioBPTS Income/yrGBDC PortfolioGBDC Income/yrGap
1$13,133$2,433.09$12,490$1,790.28+$643.00BPTS
2$17,039$2,986.35$16,522$3,157.73+$517.00BPTS
3← crossover$21,852$3,621.00$23,578$5,898.68$1.7KGBDC
4$27,722$4,340.18$37,115$11,886.75$9.4KGBDC
5$34,809$5,145.80$66,136$26,423.57$31.3KGBDC
6$43,284$6,038.47$137,257$66,491.44$94.0KGBDC
7$53,331$7,017.47$341,734$194,868.54$288.4KGBDC
8$65,145$8,080.76$1,050,788$685,133.02$985.6KGBDC
9$78,930$9,225.06$4,099,314$2,974,971.01$4.02MGBDC
10$94,901$10,445.94$20,775,530$16,389,263.41$20.68MGBDC

BPTS vs GBDC: Complete Analysis 2026

BPTSStock

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.

Full BPTS Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this BPTS vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BPTS vs SCHDBPTS vs JEPIBPTS vs OBPTS vs KOBPTS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.